Zentek Ltd. Provides Preliminary Update on Influenza Countermeasure

Zentek Ltd. has announced the successful completion of the first in vivo tests for its lead candidate countermeasure against seasonal influenza (H1N1). The tests were conducted as part of the Innovative Solutions Canada Testing Stream, with funding of approximately $1.1 million from the Government of Canada. The countermeasure, developed using Zentek's multivalent aptamer technology, showed promising results in animal models, including improved clinical scores, increased survival rates, and reduced weight loss. The company is preparing for more comprehensive testing against H1N1 and H5N1 strains. Zentek's technology aims to provide both seasonal and pandemic applications, addressing a significant global health need.